FDA application for promising oral MS drug, BG-12
FDA application for promising oral MS drug, BG-12
Biogen Idec Inc., a Weston-based biotechnology company known for its multiple sclerosis drugs, said it has submitted a New Drug Application to federal regulators to get approval to market a potential new MS treatment known as BG-12.
In December, Biogen Idec shares hit their high for 2011 after the company released promising results from a clinical trial of BG-12.
BG-12, the company’s designation for dimethyl fumarate, would be taken twice a day in pill form, and it is designed to treat of relapsing-remitting multiple sclerosis, sometimes called RRMS, the most common form of MS, Biogen Idec said in a press release.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 204 Views
-
Last post by tzootsi
-
- 0 Replies
- 1585 Views
-
Last post by DIM
-
- 1 Replies
- 1223 Views
-
Last post by Petr75
-
- 0 Replies
- 243 Views
-
Last post by NHE
-
- 0 Replies
- 1718 Views
-
Last post by NHE
-
- 0 Replies
- 631 Views
-
Last post by NHE
-
- 1 Replies
- 3331 Views
-
Last post by Tif
-
- 0 Replies
- 277 Views
-
Last post by DIM
-
- 2 Replies
- 1204 Views
-
Last post by DIM